<DOC>
	<DOCNO>NCT00090116</DOCNO>
	<brief_summary>Memory loss difficulty think associated Alzheimer 's disease may due chronic release brain chemical call glutamate . Glutamate help transmit message nerve cell interaction certain type receptor ( N-methyl-D-aspartate , NMDA ) cell . Neramexane new drug block effect excessive glutamate receptor ( NMDA receptor antagonist ) .</brief_summary>
	<brief_title>The Safety Efficacy Neramexane Patients With Moderate Severe Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Clinical diagnosis moderate severe Alzheimer 's disease ; ambulatory patient folate deficiency ; clinically significant central nervous system disease Alzheimer 's disease ; clinically significant pulmonary , gastrointestinal , renal , hepatic , endocrine cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Neramexane</keyword>
	<keyword>NMDA receptor antagonist</keyword>
	<keyword>Memory Loss</keyword>
	<keyword>Alzheimer Disease</keyword>
</DOC>